Romiplostim.
Author(s): Cines DB, Yasothan U, Kirkpatrick P
Affiliation(s): Douglas B. Cines is in the Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. dcines@mail.med.upenn.edu
Publication date & source: 2008-11, Nat Rev Drug Discov., 7(11):887-8.
Publication type: News
In August 2008, romiplostim (Nplate; Amgen), a thrombopoietin receptor agonist, was approved by the US FDA for the treatment of thrombocytopaenia in patients with chronic immune thrombocytopaenic purpura who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
|